Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324138424> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2324138424 endingPage "S41" @default.
- W2324138424 startingPage "S40" @default.
- W2324138424 abstract "Analysis of data from 2 double-blind, placebo controlled trials (ULTRA 1 and 2) revealed that adalimumab (ADA) maintenance therapy reduces hospitalization in patients with moderate to severe ulcerative colitis (UC) through Week 52.1 The impact of ADA induction dosing on hospitalization and colectomy has not yet been reported. We assessed the effect of a 160/80/40 mg ADA induction regimen (160 mg at Week 0 and 80 mg at Week 2 followed by adalimumab 40 mg every other week [eow] at Week 4 and Week 6) on the risk of hospitalizations (all-cause, UC-related, and UC- or drug-related) and colectomy during the first 8 weeks of these 2 trials. The pooled dataset included 963 patients (480 ADA, 483 placebo [PBO]). Hospitalization and colectomy events were based on safety reports reviewed by 2 gastroenterologists who were blinded to treatment. Because the exposure was similar between treatment groups, the risk of hospitalizations and colectomies between the groups was compared using Chi-square tests. Significant reductions in the risk of all-cause (40%), UC-related (50%), and UC- or drug-related (47%) hospitalizations were observed in the ADA group compared with PBO (table, P < .05 for all). Although not statistically significant, the relative risk for colectomy was lower in the ADA group compared with PBO (relative risk: 0.8, P < .770). Patients who received 160/80/40 mg ADA induction dosing had a significantly lower risk of all-cause, UC-related, and UC- and drug-related hospitalizations compared with PBO during the first 8 weeks of therapy. The incidence of colectomy was non-significantly lower in patients receiving ADA induction therapy vs. PBO. These data further support a favorable benefit/risk profile of ADA in UC." @default.
- W2324138424 created "2016-06-24" @default.
- W2324138424 creator A5018825142 @default.
- W2324138424 creator A5029565356 @default.
- W2324138424 creator A5032150391 @default.
- W2324138424 creator A5040838985 @default.
- W2324138424 creator A5048464948 @default.
- W2324138424 creator A5050304186 @default.
- W2324138424 creator A5056966450 @default.
- W2324138424 creator A5079729596 @default.
- W2324138424 date "2012-12-01" @default.
- W2324138424 modified "2023-09-26" @default.
- W2324138424 title "Adalimumab Induction Dose Reduces Hospitalization Risk in Patients With Ulcerative Colitis During the First 8 Weeks of Therapy" @default.
- W2324138424 doi "https://doi.org/10.1097/00054725-201212001-00094" @default.
- W2324138424 hasPublicationYear "2012" @default.
- W2324138424 type Work @default.
- W2324138424 sameAs 2324138424 @default.
- W2324138424 citedByCount "1" @default.
- W2324138424 countsByYear W23241384242016 @default.
- W2324138424 crossrefType "journal-article" @default.
- W2324138424 hasAuthorship W2324138424A5018825142 @default.
- W2324138424 hasAuthorship W2324138424A5029565356 @default.
- W2324138424 hasAuthorship W2324138424A5032150391 @default.
- W2324138424 hasAuthorship W2324138424A5040838985 @default.
- W2324138424 hasAuthorship W2324138424A5048464948 @default.
- W2324138424 hasAuthorship W2324138424A5050304186 @default.
- W2324138424 hasAuthorship W2324138424A5056966450 @default.
- W2324138424 hasAuthorship W2324138424A5079729596 @default.
- W2324138424 hasBestOaLocation W23241384241 @default.
- W2324138424 hasConcept C126322002 @default.
- W2324138424 hasConcept C141071460 @default.
- W2324138424 hasConcept C142724271 @default.
- W2324138424 hasConcept C204787440 @default.
- W2324138424 hasConcept C27081682 @default.
- W2324138424 hasConcept C2776667177 @default.
- W2324138424 hasConcept C2777288759 @default.
- W2324138424 hasConcept C2779134260 @default.
- W2324138424 hasConcept C2780132546 @default.
- W2324138424 hasConcept C2780479503 @default.
- W2324138424 hasConcept C2781413609 @default.
- W2324138424 hasConcept C71924100 @default.
- W2324138424 hasConcept C90924648 @default.
- W2324138424 hasConceptScore W2324138424C126322002 @default.
- W2324138424 hasConceptScore W2324138424C141071460 @default.
- W2324138424 hasConceptScore W2324138424C142724271 @default.
- W2324138424 hasConceptScore W2324138424C204787440 @default.
- W2324138424 hasConceptScore W2324138424C27081682 @default.
- W2324138424 hasConceptScore W2324138424C2776667177 @default.
- W2324138424 hasConceptScore W2324138424C2777288759 @default.
- W2324138424 hasConceptScore W2324138424C2779134260 @default.
- W2324138424 hasConceptScore W2324138424C2780132546 @default.
- W2324138424 hasConceptScore W2324138424C2780479503 @default.
- W2324138424 hasConceptScore W2324138424C2781413609 @default.
- W2324138424 hasConceptScore W2324138424C71924100 @default.
- W2324138424 hasConceptScore W2324138424C90924648 @default.
- W2324138424 hasLocation W23241384241 @default.
- W2324138424 hasOpenAccess W2324138424 @default.
- W2324138424 hasPrimaryLocation W23241384241 @default.
- W2324138424 hasRelatedWork W1946705845 @default.
- W2324138424 hasRelatedWork W1968760412 @default.
- W2324138424 hasRelatedWork W2020873782 @default.
- W2324138424 hasRelatedWork W2078963201 @default.
- W2324138424 hasRelatedWork W2117513967 @default.
- W2324138424 hasRelatedWork W2118538298 @default.
- W2324138424 hasRelatedWork W2325238644 @default.
- W2324138424 hasRelatedWork W2789863584 @default.
- W2324138424 hasRelatedWork W2978251422 @default.
- W2324138424 hasRelatedWork W3199910576 @default.
- W2324138424 hasVolume "18" @default.
- W2324138424 isParatext "false" @default.
- W2324138424 isRetracted "false" @default.
- W2324138424 magId "2324138424" @default.
- W2324138424 workType "article" @default.